Skip to main content
Everything PR News
Social Media

J&J PR Strategy: Tylenol Recall to $5.5 Billion Talc Deal

EPR Editorial TeamEPR Editorial Team8 min read
Share
Johnson & Johnson PR: Tylenol to the Talc Deal
Johnson & Johnson PR: Tylenol to the Talc Deal

Johnson & Johnson's public relations strategy rests on one document, the 1943 Credo, which ranks patients first and stockholders last. J&J used it to run the 1982 Tylenol recall of 31 million bottles, then spent more than a decade defending talc and opioid claims. On July 27, 2026, it announced a $5.5 billion talc settlement covering about 76,000 ovarian cancer claims.

Updated November 2, 2026. Settlement terms are as announced on July 27, 2026.

What is Johnson & Johnson in 2026?

Johnson & Johnson is a New Jersey healthcare company that sells prescription medicines and medical devices, after it spun its consumer health business out as Kenvue in 2023.

Kenvue is the company that now makes Tylenol, Band-Aid, Listerine and Neutrogena. DePuy Synthes is J&J's orthopaedics unit, which J&J plans to separate.

FactDetail
2025 sales outlook$93.5 billion to $93.9 billion, J&J's guidance in October 2025, reported by Reuters via Pharmalive
MedTech sales, 2025$33.8 billion, per J&J's 2025 Form 10-K
Orthopaedics sales, 2025$9.3 billion, with separation announced in October 2025 and completion targeted within 18 to 24 months
KenvueKimberly-Clark agreed in November 2025 to buy it for $48.7 billion

What does the Johnson & Johnson Credo say?

The Johnson & Johnson Credo is a one-page values statement that Robert Wood Johnson, company chairman from 1932 to 1963, wrote in 1943, just before J&J went public, according to J&J's own Credo page.

The Credo names patients, doctors, nurses, mothers and fathers as the first responsibility and employees as the second. It closes with the line "Our final responsibility is to our stockholders," and says stockholders should earn a fair return when the other duties are met.

Why it works: A ranking written before a crisis lets executives decide in hours instead of arguing over priorities. James Burke, J&J's CEO in 1982, said, "The credo is all about the consumer," in Wharton's 2012 tribute. The measurable result was a recall decision made without a boardroom fight over who comes first.

Sponsored · 5WWhere does your brand rank in ?Buyers ask AI before they search. 5W builds the footprint that gets your brand named in the answer.Talk to 5W212.999.5585info@5wpr.com

How did Johnson & Johnson run the 1982 Tylenol recall?

Johnson & Johnson recalled 31 million bottles of Tylenol and spent $100 million after seven people near Chicago died from cyanide-laced Extra-Strength capsules in late September 1982, Wharton reports.

Wharton reports that J&J's market share dropped to 7% after the deaths. J&J relaunched the product about two months later in tamper-resistant packaging. The Boston Globe's obituary of Burke credits the episode with the first tamper-resistant packaging, and J&J communications executive Steve Dnistrian told the Associated Press that Burke announced the decision to seize all Tylenol capsules at a press conference.

MoveWhat J&J didWhat to copy
Recall scopePulled 31 million bottles nationwideSize the response to the risk, not to the legal minimum
Executive visibilityBurke announced the capsule seizure at a press conferencePut the CEO in front of the decision
Product fixRelaunched about two months later in tamper-resistant packagingPair the apology with a physical change

EPR's 1982 Tylenol case file covers the full timeline. EPR's Tylenol crisis history covers the later 2010 recalls and the 2025 autism dispute.

How did Johnson & Johnson answer the 2018 Reuters talc investigation?

Johnson & Johnson answered the December 14, 2018 Reuters investigation by denying it outright and buying national advertising, a very different playbook from the 1982 recall. Reuters reported that the company knew for decades that asbestos was sometimes found in its Baby Powder, and J&J called the story "an absurd conspiracy theory," according to the AFP wire report.

J&J's shares closed down about 10% on the day the story ran, wiping roughly $40 billion from its market value, the Guardian reported. On the following Monday, Reuters reported that J&J ran full-page newspaper ads defending the product, released a video from CEO Alex Gorsky saying Baby Powder had never contained asbestos, and pointed readers to a talc facts website.

J&J also posted a point-by-point rebuttal, published on its own site, saying Reuters had "misled its readers." Gorsky then went on CNBC's "Mad Money" and, in Reuters' account, invoked the Tylenol response as proof the company could be trusted to address safety problems.

EPR's reading is that the two cases differ in one respect. In 1982 the Credo led to a visible product action that anyone could verify. In 2018 the message was that nothing needed fixing, so the Tylenol comparison drew attention to what J&J was not changing.

How did the opioid cases and bankruptcy attempts shape the story?

Johnson & Johnson settled most opioid claims for a total of $5 billion and then lost years to three failed talc bankruptcy attempts, so by 2026 its reputation depended on litigation calendars as much as on messaging.

In its 2022 Form 10-Q, J&J said it agreed in October 2020 to an all-in opioid settlement of $5 billion with states, cities, counties and tribal governments, finalized the terms in July 2021, and made the agreement effective in April 2022 after 45 states, five territories and the District of Columbia elected to participate. The filing says the agreement is not an admission of liability. In November 2021 the Oklahoma Supreme Court, in a 5-1 decision, reversed a $465 million judgment against J&J that the state had won over opioid marketing.

The talc route was slower. According to Reuters reporting carried by The Nation Thailand, J&J moved talc liabilities into new entities starting in 2021 and filed three bankruptcy cases, and each was dismissed. The third, filed by Red River Talc in September 2024, was refused confirmation on March 31, 2025. J&J then went back to defending claims in civil court and reversed about $7 billion it had set aside for the bankruptcy deal.

What is the Johnson & Johnson talc litigation?

The Johnson & Johnson talc litigation is a decade-long set of lawsuits alleging that J&J's baby powder and other talc products cause cancer, a claim J&J denies.

J&J stopped selling talc-based baby powder in the United States in 2020 and switched to cornstarch, Reuters reported, via Insurance Journal. The company then tried to resolve the claims through a shell company's bankruptcy. Those attempts failed, and the cases sat on hold for more than three years before they resumed in March 2025.

DateEvent
December 14, 2018Reuters publishes its talc investigation, and J&J shares fall about 10%
2020J&J stops selling talc-based baby powder in the United States
March 31, 2025A bankruptcy court refuses to confirm the Red River Talc plan, and litigation resumes
July 27, 2026J&J announces a $5.5 billion settlement of ovarian cancer claims

The settlement covers about 76,000 ovarian cancer claims and becomes final only if 95% of claimants accept it. J&J expects to pay $3 billion in 2027. Plaintiffs' lawyer Chris Seeger said the total could reach $7 billion because the deal sets no cap, per Reuters via the Irish Times. The agreement applies to existing claims and does not address future lawsuits.

The timing mattered. A week before the announcement, Reuters reported, the federal judge overseeing the cases ordered plaintiffs to show why their claims should not be dismissed for lack of specific-causation evidence. J&J litigation vice president Erik Haas called the claims "meritless" while saying the company wanted closure, and the company says it has also settled about 95% of filed mesothelioma lawsuits.

How has Johnson & Johnson reshaped itself since 2023?

Johnson & Johnson has separated two businesses since 2023: the consumer unit that became Kenvue, and, starting in October 2025, the DePuy Synthes orthopaedics unit.

Under the Kenvue spinoff terms, J&J kept the talc liabilities and agreed to indemnify Kenvue in the United States and Canada, The New York Times reported, via the San Juan Daily Star.

In September 2025, President Donald Trump urged Americans not to take Tylenol, claiming its main ingredient could cause autism in children when used during pregnancy. Kenvue replied that "sound science clearly shows that acetaminophen does not cause autism." Texas Attorney General Ken Paxton then sued both Kenvue and J&J, alleging deceptive marketing of Tylenol. The Texas suit shows that a spinoff changes who owns a brand, not who gets named in a lawsuit.

What should communications teams take from Johnson & Johnson?

Communications teams should take five decisions from Johnson & Johnson, each tied to a dated event.

LessonEvidenceAction
Write the priority order before the crisisThe Credo dates to 1943, and Burke cited it in 1982Draft a one-page ranking of whom the company serves first and get the CEO to sign it
Match the answer to the evidence you can showIn 2018 J&J denied the Reuters story and ran ads while shares fell about 10%Before replying to an investigative report, list which claims you can document line by line
Count the cost of delayThe bankruptcy route froze talc cases for more than three years before the 2026 settlementAsk legal counsel whether the chosen route leaves the story open for years
Write the settlement statement as one documentJ&J paired a $5.5 billion payment with a denial and a call for closureDraft the denial and the closure language together, because each sentence will be quoted alone
A spinoff does not end the storyThe Texas suit named both J&J and KenvueMap every brand and liability claim before announcing a separation, and write a Q&A for both companies

Put the priority order in writing this quarter, then test it against your three worst scenarios. EPR's guide to building a crisis communications plan and its crisis PR pillar cover the next steps, and EPR's pharma coverage places J&J among its peers.

Frequently Asked Questions

What is the Johnson & Johnson Credo?

The Johnson & Johnson Credo is a one-page values statement written in 1943 by Robert Wood Johnson. It ranks patients and users first, employees second, and stockholders last.

How much did the 1982 Tylenol recall cost?

The 1982 Tylenol recall pulled 31 million bottles and cost Johnson & Johnson $100 million, according to Wharton.

Does Johnson & Johnson still own Tylenol?

No. Kenvue makes Tylenol, and Kimberly-Clark agreed in November 2025 to buy Kenvue for $48.7 billion.

How large is the Johnson & Johnson talc settlement?

Johnson & Johnson announced a $5.5 billion settlement on July 27, 2026, covering about 76,000 ovarian cancer claims, and it becomes final only if 95% of claimants accept.

How did Johnson & Johnson respond to the 2018 Reuters talc report?

Johnson & Johnson called the Reuters story false, posted a rebuttal on its website, and ran full-page ads in major newspapers on December 17, 2018. CEO Alex Gorsky also released a video saying Baby Powder has never contained asbestos.

How much did Johnson & Johnson pay to settle opioid claims?

Johnson & Johnson agreed to an all-in opioid settlement of up to $5 billion with states, cities, counties and tribal governments, which became effective in April 2022, according to its Form 10-Q. The company says the agreement is not an admission of liability.

EPR Editorial Team
Written by
EPR Editorial Team

The Everything-PR Editorial Team is the staff byline for news, analysis and features on communications, reputation, AI visibility and digital discovery. Everything-PR has published since 2009. AI tools assist with research and drafting, and every article is reviewed by a human editor before publication. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.

Related reading

Other news

See all

Most brands are invisible inside AI search. Is yours?

EPR publishes the data every week.

Free. Weekly. Unsubscribe anytime.